Vladislav Shestakov, Director, FSI “State Institute of Drugs and Good Practices” spoke at the inauguration of the scientific and practical conference “REGLEK 2022”

The REGLEK 2022 conference started on April 26 and will last until April 29. The conference traditionally functions as a platform for an inter-institutional dialogue, that raises topical issues related to expert evaluation and registration of drugs, while the participants have an opportunity to approach representatives of regulatory authorities directly, put their questions and get an expert assessment of the current situation.

When addressing the guests and participants of the conference, Director, FSI “SID & GP”, Russian Ministry of Industry and Trade, Vladislav Shestakov, emphasized that at present, the matter of procurement of medicines for the citizens of Russia amid economic sanctions against our country remained the most acute one, along with the issue of import phase-out at all the stages of pharmaceutical manufacturing – from the supply of API intermediates and auxiliary substances to the introduction of a finished product into commerce.

“Now, the concern of every pharmaceutical manufacturer and supplier is to sustain a balance between ensuring the necessary stock of medicines and meeting all the pharmaceutical quality and safety requirements”, Vladislav Shestakov noted in his speech. “The APIs and medications manufactured in and imported into Russia should comply with the all the requirements approved by the Russian Government, despite the fact that a number of amendments simplifying some procedures have been made”.